ARCHIVE

• Fujisawa Licenses GPCR Drug Target from TaiGen
  March 3, 2003

• Shionogi Expects Sharp Recovery from FY2003
  March 3, 2003

• Kaken to Codevelop Antifungals with Elitra of the US
  March 3, 2003

• NBI's AII Receptor Antagonist Micardis Off to Strong Start
  March 3, 2003

• Global CRO Market Grew to US$7 Billion in 2001: 6th Nomura Bioconference
  March 3, 2003

• Dainippon Introduces New System to Boost R&D Efficiency
  March 3, 2003

• PERSS SEMINAR
  March 3, 2003

• Santen's New Mid-term Plan Focuses on Profits, Stronger R&D
  March 3, 2003

• RESEARCH & DEVELOPMENT NEWS IN BRIEF
  March 3, 2003

• Prices Settled for 96% of Customers by Year-end: Suzuken
  March 3, 2003

• Anthelios XL Sunscreen to Protect against UV Radiation: L'oreal Seminar
  March 3, 2003

• End-of-year Price Agreement Rate Up 15-20% vs FY2000: Azwell
  March 3, 2003

• DIAGNOSTIC NEWS IN BRIEF
  March 3, 2003

• Intellectual Property Rights Must Be Considered Together with NHI Price System: FPMAJ President
  March 3, 2003

• REGULATORY NEWS IN BRIEF
  February 24, 2003

• DIAGNOSTIC NEWS IN BRIEF
  February 24, 2003

• Small, Mid-sized Makers Should Focus on Improved Drugs: Mr Seko of PMSRL
  February 24, 2003

• MEDICAL FACILITIES & NURSING CARE NEWS IN BRIE
  February 24, 2003

• Mochida to Complete Self-supporting System by Splitting Off Its Core Businesses
  February 24, 2003

• Iressa Expert Committee Issues Interim Report
  February 24, 2003

ページ

• « 先頭
• ‹ Prev
• …
• 615
• 616
• 617
• 618
• 619
• 620
• 621
• 622
• 623
• …
• Next ›
• 最終 »